While it makes sense for value assessment to be woven into healthcare decision making, relying on a single method to measure value and using this metric to restrict treatment access is shortsighted. IVI's Jennifer Bright [...]
There isn't an easy answer to assessing value in healthcare, but IVI is working to tackle the problems through considerable research and experimentation by developing an open-source value platform that considers no only clinical factors, [...]
Is Using Centralized Value Assessment to Make Centralized Pricing Decisions the Most Effective Path Forward?
The Pink Sheet article described comment letters to HHS’ drug pricing blueprint recommending that cost-effectiveness analyses by ICER could help promote value-based pricing in government-sponsored insurance. While IVI concurs value assessment is noble, worthwhile and [...]
IVI Provides Insight into CVS Health’s Decision to Include Cost-per-QALY Analyses from ICER into Formulary Decision-Making
CVS Health's pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI's Director [...]
PRESS RELEASE: IVI Responds to HHS’ Blueprint Saying Lowering Healthcare Costs Requires Improving Value Assessment
IVI Says Moving Beyond Cost Effectiveness by Evaluating Treatments Based on Unique Patient Characteristics and Preferences is Imperative Los Angeles, CA – July 16, 2018 -- If we are going to truly harness data [...]
In an op-ed published by Fierce Healthcare, Director of Scientific Communications, Mark Linthicum discusses current shortfalls of value assessment and what is needed to move to value assessment 2.0. Read the full article here.
Los Angeles, CA -- June 20, 2018 -- Oncology is both an area of immense clinical need and a primary driver of healthcare spending. As a result, cancer care is a focus of extensive [...]
Measuring value in healthcare, which frequently takes the perspective of a single payer managing population health and costs, needs to evolve to include diverse perspectives and provide relevant and actionable information on value to [...]
PRESS RELEASE: IVI’s Open-Source Value Project Produces Actionable Data on Value of Rheumatology Treatment Sequencing Designs
Washington, D.C. -- June 14, 2018 -- Measuring value in healthcare, which traditionally takes the perspective of a single payer managing population health and costs, needs to evolve to include diverse perspectives and provide [...]
The 2018 BIO International Convention will be held in Boston, MA from June 4th through June 7th. IVI’s Jennifer Bright (Acting Executive Director) and Mark Linthicum (Director of Scientific Communications) are among the speakers invited [...]
IVI Demonstrates Commitment to Patient Involvement with Release of “Partnering with Patients” Principles
To demonstrate IVI’s commitment to patient involvement and ensure that the patient perspective is represented in our work, IVI recently developed several documents enumerating the principles and practices that guide this vital partnership. These documents offer detail about the [...]